Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

An N-terminal-truncated isoform of FAM134B (FAM134B-2) regulates starvation-induced hepatic selective ER-phagy.

Kohno S, Shiozaki Y, Keenan AL, Miyazaki-Anzai S, Miyazaki M.

Life Sci Alliance. 2019 May 17;2(3). pii: e201900340. doi: 10.26508/lsa.201900340. Print 2019 Jun.

2.

The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.

Shiozaki Y, Okamura K, Kohno S, Keenan AL, Williams K, Zhao X, Chick WS, Miyazaki-Anzai S, Miyazaki M.

J Biol Chem. 2018 Nov 2;293(44):17008-17020. doi: 10.1074/jbc.RA118.004706. Epub 2018 Sep 12.

3.

Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.

Miyazaki-Anzai S, Masuda M, Kohno S, Levi M, Shiozaki Y, Keenan AL, Miyazaki M.

J Lipid Res. 2018 Sep;59(9):1709-1713. doi: 10.1194/jlr.M087239. Epub 2018 Jul 5.

PMID:
29976576
4.

Different effects of global osteopontin and macrophage osteopontin in glomerular injury.

Trostel J, Truong LD, Roncal-Jimenez C, Miyazaki M, Miyazaki-Anzai S, Kuwabara M, McMahan R, Andres-Hernando A, Sato Y, Jensen T, Lanaspa MA, Johnson RJ, Garcia GE.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F759-F768. doi: 10.1152/ajprenal.00458.2017. Epub 2018 May 2.

PMID:
29717936
5.

Activating transcription factor-4 promotes mineralization in vascular smooth muscle cells.

Masuda M, Miyazaki-Anzai S, Keenan AL, Shiozaki Y, Okamura K, Chick WS, Williams K, Zhao X, Rahman SM, Tintut Y, Adams CM, Miyazaki M.

JCI Insight. 2016 Nov 3;1(18):e88646. doi: 10.1172/jci.insight.88646.

6.

C/EBPβ in bone marrow is essential for diet induced inflammation, cholesterol balance, and atherosclerosis.

Rahman SM, Baquero KC, Choudhury M, Janssen RC, de la Houssaye BA, Sun M, Miyazaki-Anzai S, Wang S, Moustaid-Moussa N, Miyazaki M, Friedman JE.

Atherosclerosis. 2016 Jul;250:172-9. doi: 10.1016/j.atherosclerosis.2016.03.040. Epub 2016 Apr 1.

7.

Saturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity.

Masuda M, Miyazaki-Anzai S, Keenan AL, Okamura K, Kendrick J, Chonchol M, Offermanns S, Ntambi JM, Kuro-O M, Miyazaki M.

J Clin Invest. 2015 Oct 26;125(12):4544-58. doi: 10.1172/JCI82871.

8.

Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.

Miyazaki-Anzai S, Masuda M, Levi M, Keenan AL, Miyazaki M.

PLoS One. 2014 Sep 19;9(9):e108270. doi: 10.1371/journal.pone.0108270. eCollection 2014.

9.

Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.

Miyazaki-Anzai S, Masuda M, Demos-Davies KM, Keenan AL, Saunders SJ, Masuda R, Jablonski K, Cavasin MA, Kendrick J, Chonchol M, McKinsey TA, Levi M, Miyazaki M.

J Am Heart Assoc. 2014 Jun 24;3(3):e000949. doi: 10.1161/JAHA.114.000949.

10.

PERK-eIF2α-ATF4-CHOP signaling contributes to TNFα-induced vascular calcification.

Masuda M, Miyazaki-Anzai S, Levi M, Ting TC, Miyazaki M.

J Am Heart Assoc. 2013 Sep 5;2(5):e000238. doi: 10.1161/JAHA.113.000238.

11.

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.

Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perović-Ottstadt S, Schlüter T, Kinzel O, Krol HD, Deuschle U, Burnet M, Levi M, Schmitz G, Miyazaki M, Kremoser C.

J Pharmacol Exp Ther. 2012 Dec;343(3):556-67. doi: 10.1124/jpet.112.196519. Epub 2012 Aug 23.

PMID:
22918042
12.

Activating transcription factor 4 regulates stearate-induced vascular calcification.

Masuda M, Ting TC, Levi M, Saunders SJ, Miyazaki-Anzai S, Miyazaki M.

J Lipid Res. 2012 Aug;53(8):1543-52. doi: 10.1194/jlr.M025981. Epub 2012 May 23.

13.

Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging.

Lim RS, Suhalim JL, Miyazaki-Anzai S, Miyazaki M, Levi M, Potma EO, Tromberg BJ.

J Lipid Res. 2011 Dec;52(12):2177-86. doi: 10.1194/jlr.M018077. Epub 2011 Sep 23.

14.

Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells.

Ting TC, Miyazaki-Anzai S, Masuda M, Levi M, Demer LL, Tintut Y, Miyazaki M.

J Biol Chem. 2011 Jul 8;286(27):23938-49. doi: 10.1074/jbc.M111.237065. Epub 2011 May 19.

15.

Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.

Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, Urbanek C, Solis N, Scherzer P, Lewis L, Gonzalez FJ, Adorini L, Pruzanski M, Kopp JB, Verlander JW, Levi M.

Diabetes. 2010 Nov;59(11):2916-27. doi: 10.2337/db10-0019. Epub 2010 Aug 10.

16.

Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.

Miyazaki-Anzai S, Levi M, Kratzer A, Ting TC, Lewis LB, Miyazaki M.

Circ Res. 2010 Jun 25;106(12):1807-17. doi: 10.1161/CIRCRESAHA.109.212969. Epub 2010 Apr 29.

17.

Multimodal CARS microscopy determination of the impact of diet on macrophage infiltration and lipid accumulation on plaque formation in ApoE-deficient mice.

Lim RS, Kratzer A, Barry NP, Miyazaki-Anzai S, Miyazaki M, Mantulin WW, Levi M, Potma EO, Tromberg BJ.

J Lipid Res. 2010 Jul;51(7):1729-37. doi: 10.1194/jlr.M003616. Epub 2010 Mar 5.

18.

The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.

Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, Scherzer P, Lewis L, Miyazaki-Anzai S, Levi M.

Am J Physiol Renal Physiol. 2009 Dec;297(6):F1587-96. doi: 10.1152/ajprenal.00404.2009. Epub 2009 Sep 23.

19.

Differential regulation of the renal sodium-phosphate cotransporters NaPi-IIa, NaPi-IIc, and PiT-2 in dietary potassium deficiency.

Breusegem SY, Takahashi H, Giral-Arnal H, Wang X, Jiang T, Verlander JW, Wilson P, Miyazaki-Anzai S, Sutherland E, Caldas Y, Blaine JT, Segawa H, Miyamoto K, Barry NP, Levi M.

Am J Physiol Renal Physiol. 2009 Aug;297(2):F350-61. doi: 10.1152/ajprenal.90765.2008. Epub 2009 Jun 3.

20.

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.

Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D.

J Lipid Res. 2009 Feb;50(2):312-26. doi: 10.1194/jlr.M800376-JLR200. Epub 2008 Sep 23.

Supplemental Content

Loading ...
Support Center